Back

GENZ-AF-IBD study design: a hybrid phase 4 clinical equivalence trial using AI-based synthetic control arms to compare generic apixaban with the originator in patients with atrial fibrillation

29 August 2026 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Data-driven cardiovascular medicine: from population health to clinical decision support Trial Design ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Maria Lucia Narducci

IRCCS Foundation Agostino Gemelli University Hospital, Rome (Italy)

6 More presentations in this session

Presentation thumbnail
Component network meta-regression of ARNI and guideline therapy intensity in HFrEF: quantifying additive effects on HFH
Doctor P. Amornritvanich (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Effects of short-term exposures to air temperature and temperature variability on blood pressure and heart rate in the German National Cohort
Doctor I. Moreno Velasquez (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Mobilizing core and country-tailored implementation strategies to accelerate Lipoprotein(a) testing across Europe: findings from the Lp(a)CCELERATE contextual analysis
Doctor J. Brandts (Frankfurt, DE)
Abstract Slides Video
Presentation thumbnail
Association of smartphone ownership with health literacy, lifestyle behaviors, and cardiovascular outcomes among cardiology outpatients
Doctor M. Saito (Ozu, JP)
Abstract Slides Video
Presentation thumbnail
Machine learning–based decision support for coronary angiography referral in vascular surgery patients
Doctor B. Vucurevic (Belgrade, RS)
Abstract Slides Video

Access the full session

Session thumbnail
Data-driven cardiovascular medicine: from population health to clinical decision support

The Event

Event poster

ESC Congress 2026

29 August 2026 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Using artificial intelligence agents to run digital clinical trials within large registries: is this the future?
30 August 2026
thumbnail
Congress Presentation
Geranylgeranylacetone as prevention for postoperative Atrial Fibrillation (GENIALITY trial)
29 August 2025
thumbnail
Congress Presentation
Comparing the real-world and clinical trial bleeding rates associated with oral anticoagulation treatment for atrial fibrillation
2 September 2024
thumbnail
Congress Presentation
Extra-pulmonary vein drivers as a potential mechanism of the antiarrhythmic drug-resistant atrial fibrillation after catheter ablation: Digital twin-guided virtual drug test
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources